Coming off Mounjaro

What makes tirzepatide different

Tirzepatide acts on two receptors, GIP and GLP-1, where semaglutide acts on one. That is the pharmacological headline, and in practice it shows up as a different dose ladder, a different maximum dose, and a different clearance curve.

The clearance difference is the one that matters when you stop. Tirzepatide's elimination half-life is about 120 hours — roughly five days — against about a week for semaglutide. Five half-lives is around 25 days rather than 34. You can run your own dates through the half-life calculator.

Practically, that means the fade after a final Mounjaro dose is a little steeper. Not dramatically so, and not in a way that changes the plan, but enough that people who have been on both often describe the tirzepatide trough as more noticeable late in the week.

The clearance timeline after your last dose

None of this is withdrawal. GLP-1 and dual-agonist medications do not cause physical dependence, and stopping does not produce a withdrawal syndrome. What is happening is that a drug effect is ending — which feels like something, but is a different thing.

What SURMOUNT-4 found about stopping

SURMOUNT-4 is the trial that tested this directly. Participants took tirzepatide for 36 weeks, then 670 of them were randomised to either 52 more weeks of treatment or placebo.

Among those who had achieved at least 10% weight reduction during the open-label phase, withdrawing tirzepatide led most to regain 25% or more of the weight they had lost within the year. A later post-hoc analysis published in JAMA Internal Medicine found that the cardiometabolic improvements moved back alongside the weight — the benefits were not retained independently of the treatment.

That last point is the one worth carrying into an appointment. Weight regain is the visible part. Blood pressure, lipids and glycaemic markers drifting back is the part nobody sees happening.

Mounjaro is the diabetes brand

Mounjaro and Zepbound are the same molecule with different licensed indications: Mounjaro for type 2 diabetes, Zepbound for weight management. If you are on Mounjaro, glucose control is a stated reason you are on it, whatever else the treatment is also doing.

Stopping means blood glucose rises back toward its untreated level as the drug clears. Over time that carries the complication risk the treatment was reducing.

Switching instead of stopping

A large share of people who stop are not making a clinical decision. They are responding to cost, coverage or supply. Those have options that stopping does not.

Because Mounjaro and Zepbound are the same molecule under different indications, coverage sometimes differs between them for the same person. Which one your plan will pay for is a question with a real answer, and it is worth asking before treating discontinuation as the only route.

Switching between tirzepatide and semaglutide is a different kind of change — different molecule, different dose ladder, and not a straight milligram-for-milligram swap. The dose conversion tool shows how the schedules line up, though the actual switch is a prescriber decision.

And if the pressure is purely financial, the cost calculator at least makes the trade-off visible in cost per pound rather than as a monthly number that feels unsurvivable.

What to track through a transition

The useful signals move before the scale does, and none of them are things anyone remembers accurately three weeks later. If you are changing anything about your treatment, these four are worth writing down as they happen:

• Food noise. Intrusive food thoughts, grazing urges, whether old portions have started looking normal again. This is usually the first thing to move.
• Hunger pattern. Not just how often, but whether meals still finish the feeling.
• Weight trend, weekly. A seven-day average, not a daily number. Daily weights during a transition mostly measure hydration and generate anxiety.
• Dose history. Exact dates of every change, missed dose, dose stretch, side effect and supply gap. This is the part clinicians most often ask about and patients most often cannot answer.

The point is not to become a data project. It is that "hunger came back around week three and I was up four pounds by week six" is a conversation that produces a plan, while "I think it's been getting worse" is not.

Common questions

What happens when you stop taking Mounjaro?

Appetite and food noise return as tirzepatide clears, typically over one to three weeks, and blood glucose rises back toward its untreated level. In SURMOUNT-4, most participants who withdrew after 36 weeks of treatment regained 25% or more of the weight they had lost within a year.

Is there Mounjaro withdrawal?

No. Tirzepatide does not cause physical dependence and there is no withdrawal syndrome. What people describe as withdrawal is the return of appetite, food noise and, for people with diabetes, higher blood glucose.

How long does tirzepatide stay in your system?

The elimination half-life is about 120 hours, roughly five days, so about 97% is cleared after around 25 days. Appetite effects fade considerably sooner.

Is Mounjaro the same as Zepbound?

Same molecule, different licensed indication: Mounjaro for type 2 diabetes, Zepbound for weight management. Coverage can differ between them for the same person, which is worth checking before stopping over cost.

Can I switch from Mounjaro to Ozempic?

Switching between tirzepatide and semaglutide is possible but is not a milligram-for-milligram swap — they are different molecules with different dose ladders, and the switch usually involves re-titrating. It is a prescriber decision.

Keep reading